2023-01-18T16:30:12+00:00 2022-03-31 346565596 ERNST & YOUNG US LLP 1901 SIXTH AVENUE NORTH SUITE 1200 BIRMINGHAM AL 35203 990 2021-04-01 751835298 The Susan G Komen Breast Cancer Foundation Inc SUSA 9728551600 13770 NOEL ROAD SUITE 801889 DALLAS TX 75380 PAULA SUE SCHNEIDER PRESIDENT AND CEO 2023-01-18 true PAULA SUE SCHNEIDER 999009999 Kathy Pitts P00292940 2052512000 2021 2023-03-07 01:45:13Z SUSAN G KOMEN PAULA SUE SCHNEIDER 13770 NOEL ROAD SUITE 801889 DALLAS TX 75380 165642733 false X WWW.KOMEN.ORG X 1982 TX OUR MISSION IS TO SAVE LIVES BY MEETING THE MOST CRITICAL NEEDS IN OUR COMMUNITIES AND INVESTING IN BREAK-THROUGH RESEARCH TO PREVENT AND CURE BREAST CANCER. 18 18 556 1456 10933 0 50983746 99456148 3259501 2500 7389057 7437450 26113354 4365358 87745658 111261456 15229334 25691669 0 0 27327944 36149496 1158758 1181706 22781842 31051187 37609513 74767223 100632384 12978435 10629072 193189248 207354061 55926370 59717916 137262878 147636145 Komen's mission is to save lives by meeting the most critical needs in our communities and investing in breakthrough research to prevent and cure breast cancer. false false 40955788 4503337 -5448 PATIENT CARE AND ADVOCACY: PROVISION OF BREAST CANCER SCREENING, DIAGNOSIS, AND TREATMENT PROGRAMS THROUGH GRANTS TO OTHER NON-PROFIT ORGANIZATIONS, THIRD-PARTY CONTRACTS AND DIRECTLY BY KOMEN, WITH A SPECIAL EMPHASIS ON PATIENT NAVIGATION, ESPECIALLY IN COMMUNITIES WHERE DISPARITIES IN OUTCOMES ARE SIGNIFICANT AND/OR ACCESS IS LIMITED. SEE SCHEDULE O FOR ADDITIONAL DETAILS. 24901656 21181617 2500 GRANTS TO RESEARCH INSTITUTIONS AND OTHER NONPROFIT ORGANIZATIONS TO SUPPORT BREAST CANCER RESEARCH PROJECTS INCLUDING THOSE FOCUSED ON THE BIOLOGY OF BREAST CANCER; NEW STRATEGIES TO TREAT, DETECT, AND PREDICT RISK OF BREAST CANCER, AND UNDERSTANDING AND ADDRESSING DISPARITIES IN OUTCOMES. SEE SCHEDULE O FOR ADDITIONAL DETAILS. 65857444 true true false true false false false false true true true false false false true false true false false true true false true true false false true true true false false false false false false false false true false false false false false false false false true 133 0 true 556 true true true false false false false true true true 1 false false false false false X 18 18 false false false false false false false true true false true true true true true true true true true true false CA CO CT DC FL GA AL HI IL IN KS KY ME AK MD MA MI MN MS MO NH NJ NM NY NC ND OH OK OR PA AZ RI SC TN UT VA AR WA WV WI X X RIA WILLIAMS 9728551600 13770 NOEL ROAD SUITE 801889 DALLAS TX 75380 Ed Dandridge Chair of the Board (BEG Jun 2021 ) 1.0 0 X X 0 0 0 Jerri Johnson BOD Member (Vice Chair BEG Mar 2021 1.0 0 X X 0 0 0 Andi Owen BOD Member (BEG Mar 2021) 1.0 0 X 0 0 0 BJ Schaknowski BOD Member (BEG Mar 2022) 1.0 0 X 0 0 0 Christina Minnis BOD Member 1.0 0 X 0 0 0 Eugene Kim BOD Member (END Mar 2022) 1.0 0 X 0 0 0 Gail Heimann BOD Member (BEG Mar 2021) 1.0 0 X 0 0 0 John O'Neill BOD Member 1.0 0 X 0 0 0 Julia Harris BOD Member (BEG Mar 2021) 1.0 0 X 0 0 0 Julie Gruber BOD Member (BEG Mar 2022) 1.0 0 X 0 0 0 Kristen Racich BOD Member (BEG Mar 2022) 1.0 0 X 0 0 0 Kwanza Jones BOD Member (END Mar 2022) 1.0 0 X 0 0 0 Luke Sauter BOD Member (BEG Mar 2021) 1.0 0 X 0 0 0 Lydia The BOD Member (BEG Mar 2022) 1.0 0 X 0 0 0 Michelle Bottomley BOD Member (BEG Mar 2021) 1.0 0 X 0 0 0 Peter D Brundage BOD Member (frmr Chair, Chair end Jun 2021) 1.0 0 X 0 0 0 Renee Baker BOD Member (BEG Mar 2021) 1.0 0 X 0 0 0 Robyn Shepherd BOD Member (BEG Mar 2022) 1.0 0 X 0 0 0 Sean Slovenski BOD Member (BEG Mar 2021) 1.0 0 X 0 0 0 Susannah Gray BOD Member (END Mar 2022) 1.0 0 X 0 0 0 Traci Blunt BOD Member (BEG Mar 2021) 1.0 0 X 0 0 0 Dana Brown Chief Operating Officer 55.0 0 X 465537 0 15637 Eunice Nakamura General Counsel & Corporate Secretary 55.0 0 X 269473 0 14336 Paula Schneider President and CEO 55.0 0 X 682520 0 31412 Ria Williams Chief Financial Officer 55.0 0 X 290183 0 21782 Catherine Olivieri SVP, Human Resources 55.0 0 X 289457 0 22580 Lori Maris SVP, Ops Services & Support 55.0 0 X 243277 0 12596 Victoria Wolodzko SVP, Mission 55.0 0 X 340267 0 9729 Kari Bodell VP, Dev Progs Strat 55.0 0 X 229605 0 7955 Kimberly Sabelko VP, Sci Strat & Programs 55.0 0 X 202212 0 15723 Michelle Strong VP, Marketing Strat 55.0 0 X 225607 0 13095 Sarah Rosales VP, Corp Partnerships 55.0 0 X 233478 0 16798 Srinivasu Avadhanula VP, BI Platfm & Eng 55.0 0 X 241720 0 7910 Kimberly Johnson Former Sr. Director AAHEI 0.0 X 182424 0 1769 3895760 0 191322 92 false true false Event 360 205 N Michigan Ave Chicago IL 60601 Event Management 2349796 RKD Group LLC 3400 Waterview Parkway Richardson TX 75080 Consulting 1086596 CSM Sport & Entertainment Inc 8770 Guion Road Indianapolis IN 46268 Consulting 458250 Ernst & Young 3712 Solutions Center Chicago IL 60677 Acctg & Tax Services 329983 MSB Financial Solutions LLC 79 Cherrywood Dr Nashua NH 03062 Consulting 323309 20 262529 0 25041236 0 4527545 69624838 182327 99456148 Affiliate Treatment Assistance Fund 900099 2500 2500 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2500 1152853 0 0 1152853 0 0 0 0 3507 0 0 3507 0 0 0 0 0 0 0 0 0 0 56458504 0 50173907 0 6284597 0 6284597 0 0 6284597 977618 25041236 4150957 -3173339 0 -3173339 4642 31204 -26562 0 0 -26562 14061 25209 -11148 -11148 0 0 SHARED SERVICES 900099 5700 5700 0 0 OTHER INCOME 900099 3574 0 10933 -7359 MERGER RELATED INCOME 900099 7563626 0 0 7563626 0 0 0 0 7572900 111261456 -2948 10933 11797323 21294309 21294309 3829950 3829950 567410 567410 0 0 2708786 1405372 658068 645346 0 0 0 0 28161837 14624022 6764699 6773116 783595 402287 206904 174404 2420853 1196985 686865 537003 2074425 1082439 487763 504223 0 0 0 0 242415 97066 48283 97066 508141 57633 392894 57614 204997 204997 0 0 1181706 1181706 179154 0 179154 0 0 0 0 0 5010574 2770603 336748 1903223 16533412 8238874 130075 8164463 1863957 745583 559187 559187 0 0 0 0 198411 125740 38890 33781 276760 144731 44116 87913 0 0 0 0 211178 77693 50538 82947 0 0 0 0 0 0 0 0 900298 665856 126593 107849 543188 543188 0 0 CONSULT & PROF. FEES 6641802 5326482 556519 758801 EQUIP RENTAL & MAINT 1744826 1102803 346119 295904 EVENT PRODUCTION 108740 40854 23002 44884 MERCHANT SERVICES & BANK FEES 1367858 777580 94358 495920 1073802 534981 262329 276492 100632384 65857438 11993104 22781842 X 42779147 21416390 1814928 19547829 0 0 27119307 23067395 20276918 15045253 0 0 0 0 0 0 0 0 6957 9577 2239524 2120424 12062424 8416953 2249769 3645471 102135416 119988473 39150000 43470000 0 0 0 11357 7468 193189248 207354061 9143376 9791057 41640671 49697151 614778 229708 0 0 0 0 0 0 4527545 0 0 0 0 0 55926370 59717916 X 90698864 98403421 46564014 49232724 0 0 0 0 0 0 137262878 147636145 193189248 207354061 X 10629072 -693580 -179874 0 617649 X false true X true false X 51441732 63291987 59972314 50983746 99456148 325145927 0 0 51441732 63291987 59972314 50983746 99456148 325145927 20149718 304996209 5667273 5221701 4928838 1217543 1156360 18191715 0 124523 34200 86442 15070 3574 263809 343601451 81700047 0.8876 0.8199 X Schedule A, Part II, Line 10 Other Income DESCRIPTION - OTHER INCOME, COLUMN A - 124523.0, COLUMN B - 34200.0, COLUMN C - 86442.0, COLUMN D - 15070.0, COLUMN E - 3574.0, COLUMN F - 263809.0; RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 26906 26906 178091 178447 204997 205353 88434283 98589124 88639280 98794477 1000000 1000000 250000 250000 0 0 0 0 1000000 1000000 1000000 1000000 4000000 6000000 279269 343462 172474 204997 1000202 250000 250000 250000 250000 1000000 1500000 64115 86368 386160 26906 563549 Schedule C, Part II-A Lobbying Expenses Public policy and advocacy initiatives have the potential to impact all people touched by breast cancer. Recognizing the importance of this work to accomplish its mission, Komen supports advocacy and lobbying efforts to achieve legislative and regulatory solutions designed to support key patient protections, expand access to high-quality care and fund critical breast health programs and cancer research. 1342173 0 10613 0 5918 0 1346868 1337562 0 10279 0 5668 0 1342173 1333603 0 9803 0 5844 0 1337562 1362090 0 -4016 0 24267 204 1333603 1377855 10034 25799 0 1362090 0.74 0.24 0.02 false false 83890 66413 17477 2171260 1724500 446760 9807274 6626040 3181234 3645471 PRIVATE EQUITY FUND 43470000 F 43470000 0 X Schedule D, Part V, Line 4 Intended uses of endowment funds KOMEN HAS THREE PERMANENT ENDOWMENTS: GOODMAN-BRINKER, FIRNBERG, AND A GENERAL ENDOWMENT. THE GOODMAN-BRINKER ENDOWMENT IS FOR BREAST CANCER RESEARCH FELLOWSHIPS, THE FIRNBERG ENDOWMENT IS FOR BREAST CANCER EDUCATIONAL PROGRAMS AND RESEARCH AWARDS, AND THE GENERAL ENDOWMENT'S EARNINGS ARE RESTRICTED FOR ORGANIZATIONAL MISSION ACTIVITIES. Schedule D, Part X, Line 2 FIN 48 (ASC 740) footnote THE ORGANIZATION IS SUBJECT TO A RECOGNITION THRESHOLD AND MEASUREMENT ATTRIBUTE FOR FINANCIAL STATEMENT RECOGNITION AND MEASUREMENT OF A TAX POSITION TAKEN OR EXPECTED TO BE TAKEN IN A TAX RETURN. THERE WERE NO UNCERTAIN TAX POSITIONS RECORDED IN THE CONSOLIDATED FINANCIAL STATEMENTS AT MARCH 31, 2022 true East Asia and the Pacific 0 1 Grantmaking Patient Care 500 East Asia and the Pacific 0 2 Grantmaking Research 182226 Europe (Including Iceland and Greenland) 0 1 Fundraising Fundraising Support 13402 Europe (Including Iceland and Greenland) 0 4 Grantmaking Research 221030 Europe (Including Iceland and Greenland) 0 1 Program Services Learning Mgmt System 16189 Europe (Including Iceland and Greenland) 0 1 Program Services Legal Services 7113 Europe (Including Iceland and Greenland) 0 1 Program Services Professional Membership 3288 North America (Canada & Mexico only) 0 3 Grantmaking Research 149156 North America (Canada & Mexico only) 0 1 Program Services Advocacy 47096 North America (Canada & Mexico only) 0 1 Program Services Mission Tool Development 500639 North America (Canada & Mexico only) 0 1 Program Services Professional Membership 2000 North America (Canada & Mexico only) 0 1 Program Services Software Licenses 22482 Middle East and North Africa 0 1 Grantmaking Treatment 19998 0 19 0 0 0 19 1185119 0 1185119 East Asia and the Pacific Research 135000 Electronic Fund or Wire Transfer East Asia and the Pacific Research 47226 Electronic Fund or Wire Transfer North America (Canada & Mexico only) Research 58749 Electronic Fund or Wire Transfer North America (Canada & Mexico only) Research 74992 Electronic Fund or Wire Transfer North America (Canada & Mexico only) Research 15415 Electronic Fund or Wire Transfer Europe (Including Iceland and Greenland) Research 51878 Electronic Fund or Wire Transfer Europe (Including Iceland and Greenland) Research 74685 Electronic Fund or Wire Transfer Europe (Including Iceland and Greenland) Research 89467 Electronic Fund or Wire Transfer Sub-Saharan Africa Treatment 19998 Electronic Fund or Wire Transfer 9 0 true false true false false false Schedule F, Part I, Line 2 Procedures for monitoring use of grant funds AS OUTLINED IN KOMEN'S POLICIES AND PROCEDURES FOR RESEARCH AND TRAINING GRANTS, ALL GRANTEES ARE REQUIRED TO SUBMIT SCIENTIFIC PROGRESS REPORTS AND FINANCIAL REPORTS IN THE FORMAT REQUIRED BY KOMEN AND IN ACCORDANCE WITH THE SCHEDULE SET FORTH IN THE POLICIES AND ANY CHANGE REQUESTS THEY MAY HAVE FOR THEIR PROJECTS. ALL PROGRESS REPORTS AND REQUESTS ARE REVIEWED BY QUALIFIED STAFF. SEE SCHEDULE I, PART IV AND SCHEDULE O, PART IX, LINE 1 NARRATIVE FOR ADDITIONAL DETAILS. Schedule F, Part I, Line 3 Method used to account for expenditures on org's financial statements EAST ASIA AND THE PACIFIC-Accrual,; EUROPE (INCLUDING ICELAND AND GREENLAND)-Accrual,; MIDDLE EAST AND NORTH AFRICA-Accrual; NORTH AMERICA (CANADA & MEXICO ONLY)-Accrual Schedule F, Part II, Line 1 Method used to account for expenditures on org's financial statements EAST ASIA AND THE PACIFIC-Accrual,; EUROPE (INCLUDING ICELAND AND GREENLAND)-Accrual; NORTH AMERICA (CANADA & MEXICO ONLY)-Accrual; SUB-SAHARAN AFRICA-Accrual X X X X X X true Event 360 55 E Jackson Blvd Suite 1010 Chicago IL 60604 Fundraising Consultant false 7185057 576810 6608247 Revunami Inc 228 E 85th St Suite 9C New York NY 10028 Marketing Consultant false 20593 -20593 RKD Group LLC 3400 Waterview Parkway Suite 250 Richardson TX 75080 Fundraising Consultant false 27711220 578703 27132517 Armstrong McGuire LLC PO Box 6485 Raleigh NC 27628 Fundraising Consultant false 5600 -5600 34896277 1181706 33714571 CA CO CT DC FL GA AL HI ID IL IN IA KS KY LA ME AK MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA AZ RI SC SD TN TX UT VT VA AR WA WV WI WY Race-Walk Events 14499847 14043859 455988 0 304015 79551 117659 11009 1431367 3 Day Event 9614231 9343514 270717 0 10334 268834 293462 0 1122211 32 1904776 1653863 250913 0 31084 130022 69402 20165 261842 26018854 25041236 977618 0 345433 478407 480523 31174 2815420 4150957 -3173339 Schedule G, Part II Net Income Summary Gross receipts are reduced by the amount of fundraising contributions, per IRS instructions. The contributions for fiscal year 2022 were $25,041,236 true Baylor College of Medicine One Baylor Plaza BCM 206 Houston TX 77030 741613878 501c(3) 175000 Research Beth Israel Deaconess Medical Center 330 Brookline Avenue Boston MA 02215 042103881 501c(3) 149729 Research University of OKlahoma PO Box 36901 Oklahoma City OK 731260901 731563627 501c(3) 9539 Education Boston University 225 Bay State Rpad Boston MA 02215 042103547 501c(3) 100000 Research Brigham and Women's Hospital 181 Longwood Ave 5th Fl Boston MA 02115 042312909 501c(3) 61803 Research Cancer Care 275 Seventh Avenue New York NY 10001 131825919 501c(3) 29274 Education Columbia University Med Ctr 722 West 168th St 4th Fl New York NY 10032 135598093 501c(3) 260000 Research Dana-Farber Cancer Institute Inc 450 Brookline Ave BP 412 Boston MA 02215 042263040 501c(3) 1385042 Research Duke University Medical Center PO Box 602651 Charlotte NC 282602651 560532129 501c(3) 140000 Research Emory University 1599 Clifton Rd NE 4th Fl Atlanta GA 30322 580566256 501c(3) 148222 Research Federacio De Clubes Michoacanos 1638 S Blue Island Ave Chicago IL 60608 412061019 501c(3) 29175 Screening Fred Hutchinson Cancer Research Center PO Box 19024 Seattle WA 98109 563744111 501c(3) 225000 Research Fulton County Health Department 700 East Oak Street Canton IL 61520 376000896 501c(3) 5438 Screening Harvard Medical School Holyoke Center Room 600 1350 Massachusetts Avenue Cambridge MA 02138 042103580 501c(3) 100000 Research Indiana University (Indianapolis) Financial Mgmt Svcs PO Box 66057 Indianapolis IN 462666057 356001673 501c(3) 716595 Research Intermountain Healthcare Foundation Inc 36 South State Street Salt Lake City UT 84111 942854057 501c(3) 9375 Research Johns Hopkins University 1101 East 33rd Street Eastern C220 Baltimore MD 21218 520595110 501c(3) 834671 Research Lake County Health Department 3010 Grand Avenue Waukegan IL 60085 593502843 501c(3) 5105 Screening Leland Stanford Jr University PO Box 44253 San Francisco CA 941444253 941156365 501c(3) 200000 Research Massachusetts Institute of Technology 160 Memorial Drive Cambridge MA 02139 042103594 501c(3) 200000 Research Mayo Clinic Jacksonville Griffin Building Room 170 4500 San Pablo Road Jacksonville FL 32224 593337028 501c(3) 400000 Research McDonough County Health Department 505 E Jackson Street Macomb IL 61455 376001537 501c(3) 4419 Screening Memorial Sloan-Kettering Cancer Ctr 633 Third Avenue 28th Floor New York NY 10017 131924236 501c(3) 425000 Research Mountain Park Health Cntr 3003 N 3rd Street Suite 1600 Phoenix AZ 85012 860498020 501c(3) 16667 Education North Carolina Central University 1801 Fayetteville Street Durham NC 27707 566000730 501c(3) 50809 Research Northwestern University - Chicago 633 Clark Room G547 Evanston IL 60208 362167817 501c(3) 224933 Research Oregon Health & Science University 0690 SW Bancroft Portland OR 97239 752668014 501c(3) 468663 Research Princeton University 701 Carnegie Center Suite 413 Princeton NJ 08540 210634501 501c(3) 100000 Research Providence Portland Medical Center PO Box 13993 Portland OR 97213 930386906 501c(3) 165000 Research Roswell Park Alliance Foundation Department of Immunology Elm Carlton Streets Buffalo NY 14263 161391608 501c(3) 60000 Research Rush University Medical Center 1700 W Van Buren St Suite 250 Chicago IL 60612 362174823 501c(3) 200000 Research Stanford University PO Box 44253 San Francisco CA 941444253 941156365 501c(3) 100000 Screening Stephenson County Health Department 10 West Linden Street Freeport IL 61032 366006654 501c(3) 5125 Research SUNY at Stony Brook W5510 Melville Library Stony Brook NY 11794 141368361 501c(3) 110607 Education Supporting Our Sisters International Inc 2604 Pinebrook Ave C2 Hyattsville MD 20785 472511778 501c(3) 2500 Screening Tazewell County Health Department 21306 Illinois Rt 9 Tremont IL 615689252 376002170 501c(3) 27593 Screening The Ohio State University College 700 Childrens Drive Columbus OH 43205 316025986 501c(3) 142485 Research The University of Chicago 970 East 58th Street 3rd Fl Chicago IL 60637 362177139 501c(3) 389674 Research The Wistar Institute 3601 Spruce Street Philadelphia PA 191044265 236434390 501c(3) 165000 Research Tufts University 800 Washington Street Boston MA 02111 043400617 501c(3) 66840 Research UnityPoint Health-MethodistProctor 5409 N Knoxville Ave Peoria IL 61614 510186460 501c(3) 9928 Screening Univ of Colorado Health Sciences Cent 13001 E 17TH PLACE Denver CO 802910238 731563627 501c(3) 92496 Research Univ of North Carolina at Chapel Hill 104 Airport Drive Suite 2200 CB 1350 Chapel Hill NC 275991350 566001393 501c(3) 775531 Research Univ of Texas MD Anderson Cancer Center PO Box 4390 Houston TX 772104390 746001118 501c(3) 495766 Research University of Alabama at Birmingham 1530 3rd Avenue South Room 1170 Birmingham AL 352940111 636005396 501c(3) 90000 Research University of California at San Francisco 3333 California St Suite 315 San Francisco CA 94118 946036493 501c(3) 100000 Research Loyola University Chicago 820 N Michigan Ave Ste 1300 Chicago IL 60611 361408475 501c(3) 165000 Research University of Massachusetts Amherst Goodell Bldg Room 405 Box 33210 Amherst MA 010033210 043167352 501c(3) 37109 Research University of Michigan Alexandra Thebaud Wolverine Tower Ann Arbor MI 481091274 386006309 501c(3) 423873 Research University of North Carolina 104 Airport Drive Suite 2200 CB 1350 Chapel Hill NC 275999525 566001393 501c(3) 100000 Research University of Notre Dame du Lac 836a Grace Hall Notre Dame IN 465565612 350868188 501c(3) 60000 Research University of Pennsylvania 3451 Walnut Street P-211 Franklin Bldg Philadelphia PA 191046205 231352685 501c(3) 211881 Research University of Pittsburgh 123 University Place Suite B21 Pittsburgh PA 152132303 250966691 501c(3) 120000 Research University of Pittsburgh 3100 Cathedral Learning Pittsburgh PA 15260 250965591 501c(3) 210000 Research University of South Carolina 1600 Hampton Street Suite 404H Columbia SC 29208 576001153 501c(3) 53727 Research University of Utah 201 South Presidents Circle Room 406 Salt Lake City UT 841129020 876000525 501c(3) 220000 Research University of Washington 3917 University Way NE Seattle WA 98105 741586031 501c(3) 115000 Research UT HSC - San Antonio 7703 Floyd Curl Drive San Antonio TX 772293900 741586031 501c(3) 209959 Research UT Southwestern Medical Center 5323 Harry Hines Blvd Dallas TX 753909020 746000203 501c(3) 579255 Research Utah Cancer Control Program PO Box 144620 Salt Lake City UT 841144620 876000545 501c(3) 30 Education Valleywise Health Foundation 2901 E Camelback Rd Ste 202 Phoenix AZ 85016 860777567 501c(3) 16667 Education Vanderbilt University Medical Center Dept AT 40303 Atlanta GA 311920303 620476822 501c(3) 627363 Research Virginia Commonwealth University 800 E Leigh St Suite 3100 Richmond VA 232843039 546001758 501c(3) 75000 Research VNA of Fox Valley 400 North Highland Ave Aurora IL 60506 362182095 501c(3) 19992 Screening Wake Forest University Health Sciences Grants Mgmt Medical Ctr Blvd WinstonSalem NC 27157 223849199 501c(3) 90000 Research Wayne State University 5057 Woodward AVE 13th Floor Detroit MI 48202 366028429 501c(3) 18789 Research Winnebago County Health Department 555 NCourt St PO Box 4009 Rockford IL 611100509 364529968 501c(3) 6097 Screening Yale University 2 Whitney Avenue 6th Floor New Haven CT 06510 030179440 501c(3) 135000 Research 67 0 Patient Care Assistance @ $300 4894 1468200 0 fmv 0 Patient Care Assistance @$500 3666 1833000 0 fmv 0 Patient Care Assistance @ $750 705 528750 0 fmv 0 Schedule I, Part I, Line 2 Procedures for monitoring use of grant funds. SUSAN G. KOMEN'S (KOMEN) POLICIES FOR MANAGING GRANTS FROM THE TIME OF PRE-AWARD THROUGH CLOSEOUT ARE DESIGNED TO MAXIMIZE FLEXIBILITY WHILE MAINTAINING A HIGH STANDARD OF ACCOUNTABILITY AND PRESERVING THE INTEGRITY OF THE REVIEW AND AWARD PROCESS. KOMEN REQUIRES ALL GRANTEES TO SIGN A GRANT AGREEMENT SETTING FORTH THE TERMS OF THE GRANT, INCLUDING: PURPOSE, AMOUNT, BUDGETARY RESTRICTIONS, DURATION, PAYMENT SCHEDULE, REPORTING REQUIREMENTS, AUDIT, AND EARLY TERMINATION RIGHTS. FOR RESEARCH GRANTS, SCIENTIFIC PROGRESS AND FINANCIAL OVERSIGHT IS MONITORED THROUGHOUT THE GRANT TERM BY A PH.D. OR MASTERS-LEVEL RESEARCH GRANT MANAGER. FOR COMMUNITY HEALTH AND EDUCATION GRANTS, PROGRESS AND FINANCIAL OVERSIGHT IS MONITORED OR SUPERVISED THROUGHOUT THE GRANT TERM BY QUALIFIED PROFESSIONALS SERVING AS GRANTS MANAGERS. AS OUTLINED IN KOMEN'S POLICIES AND PROCEDURES FOR RESEARCH AND TRAINING GRANTS, GRANTEES ARE REQUIRED TO SUBMIT PROGRESS AND FINANCIAL REPORTS DETAILING PROGRESS TOWARD AIMS AND OBJECTIVES, MAJOR ACCOMPLISHMENTS, KEY DELIVERABLES AND CHALLENGES ENCOUNTERED, WITH A FULL ACCOUNTING OF GRANT FUNDS EXPENDED (ACTUAL VERSUS BUDGETED EXPENSES) AND WRITTEN JUSTIFICATION OF EXPENSES. AS APPROPRIATE, THE GRANTS MANAGER MAY CONDUCT SITE VISITS WITH GRANTEES TO GAIN A BETTER UNDERSTANDING OF THEIR WORK AND ADDRESS ANY CHALLENGES IMPACTING THE FUNDED PROGRAM. ALL GRANT FUNDS MUST BE EXPENDED IN ACCORDANCE WITH THE PROJECT'S APPROVED BUDGET AND ARE DISBURSED IN ACCORDANCE WITH THE SCHEDULE DOCUMENTED WITHIN THE GRANT AGREEMENT. REQUESTS FOR CHANGES TO THE DESIGN OF THE FUNDED PROJECT OR BUDGET ARE SUBJECT TO PRIOR APPROVAL BY KOMEN IN ACCORDANCE WITH THE TERMS OF THE GRANT AGREEMENT. AS PART OF ITS OVERSIGHT PRACTICES, THE TERMS OF THE GRANT AGREEMENT MAY PROVIDE KOMEN WITH, AMONG OTHER THINGS, THE RIGHT TO REQUEST WITH REASONABLE PRIOR NOTICE TO THE GRANTEE: (1) ADDITIONAL PROGRESS AND/OR FINANCIAL REPORTING FROM THE GRANTEE, (2) GRANTEE PARTICIPATION IN SITE VISITS, TELEPHONE CONFERENCES, PRESENTATIONS, OR OTHER SPEAKING ENGAGEMENTS, AND (3) WITH PRIOR WRITTEN NOTICE, ADJUSTMENT TO THE PROJECT REPORTING PERIOD AND ASSOCIATED DISBURSEMENT OF GRANT FUNDS AT ANY TIME DURING THE GRANT TERM. SEE SCHEDULE O, PART IX, LINE 1 NARRATIVE FOR ADDITIONAL DETAILS. X X X X X X false false false false false false false false false Dana Brown Chief Operating Officer 415375 0 46800 0 3362 0 13948 0 1689 0 481174 0 0 0 Eunice Nakamura General Counsel & Corporate Secretary 241539 0 26400 0 1534 0 8188 0 6148 0 283809 0 0 0 Paula Schneider President and CEO 609111 0 68805 0 4604 0 15875 0 15537 0 713932 0 0 0 Ria Williams Chief Financial Officer 259268 0 29046 0 1869 0 7341 0 14441 0 311965 0 0 0 Lori Maris SVP, Ops Services & Support 217465 0 24102 0 1710 0 4012 0 8584 0 255873 0 0 0 Catherine Olivieri SVP, Human Resources 256095 0 30000 0 3362 0 8941 0 13639 0 312037 0 0 0 Victoria Wolodzko SVP, Mission 302964 0 34800 0 2503 0 6710 0 3019 0 349996 0 0 0 Kimberly Johnson Former Sr. Director AAHEI 170979 0 10000 0 1445 0 0 0 1769 0 184193 0 0 0 Srinivasu Avadhanula VP, BI Platfm & Eng 216663 0 23643 0 1414 0 5964 0 1946 0 249630 0 0 0 Kari Bodell VP, Dev Progs Strat 203596 0 24600 0 1409 0 5942 0 2013 0 237560 0 0 0 Sarah Rosales VP, Corp Partnerships 213743 0 18450 0 1285 0 3525 0 13273 0 250276 0 0 0 Kimberly Sabelko VP, Sci Strat & Programs 185656 0 15000 0 1556 0 5008 0 10715 0 217935 0 0 0 Michelle Strong VP, Marketing Strat 204015 0 20000 0 1592 0 6888 0 6207 0 238702 0 0 0 X 30975 Cost X Gift bags/Gift Cards 30 41795 Cost X Goods Inventory 34 96622 Cost X Photography 1 35 Cost X Supplies 4 8900 Cost X Tickets 3 400 Cost X Travel 2 3600 Cost false false false Form 990, Part I, Line 6 VOLUNTEERS VOLUNTEERS SERVE IN A VARIETY OF WAYS, BUT THE GREATEST NUMBERS OF VOLUNTEERS ASSIST WITH THE MORE THAN PINK WALKS, RACE FOR THE CURE RUNS, AND THE SUSAN G. KOMEN 3 DAY SERIES. Form 990, Part III, Line 4 Program service accomplishments SUSAN G. KOMEN'S MISSION IS TO SAVE LIVES FROM BREAST CANCER, BY FINDING BREAKTHROUGHS TO PREVENT, DETECT, TREAT, AND CURE BREAST CANCER, AND BY MEETING MOST CRITICAL NEEDS IN COMMUNITIES TO ENSURE EVERYONE GETS THE BREAST CANCER CARE THEY NEED WHEN THEY NEED IT. KOMEN TAKES A 360 DEGREE APPROACH TO FIGHT BREAST CANCER THROUGH . RESEARCH, TO DRIVE BREAKTHROUGHS THAT WILL BRING US NEW KNOWLEDGE AND ADVANCES IN CARE FOR ALL, . COMMUNITY HEALTH, TO EMPOWER PEOPLE WITH TRUSTWORTHY INFORMATION AND SUPPORT PEOPLE IN THEIR BREAST HEALTH JOURNEY THROUGH DIRECT SERVICES, COMMUNITY PROGRAMS AND HEALTH SYSTEMS CHANGE. . AND PUBLIC POLICY, WHERE WE ADVOCATE FOR POLICIES TO CREATE SYSTEMIC AND LASTING CHANGES THAT WILL FUND AND FACILITATE RESEARCH AND ALLEVIATE THE BURDEN ON PATIENTS AND PROTECT ACCESS TO AFFORDABLE, HIGH-QUALITY HEALTH CARE FOR ALL. KOMEN IS A LEADING GLOBAL BREAST CANCER ORGANIZATION, HAVING FUNDED MORE BREAST CANCER RESEARCH THAN ANY OTHER NONPROFIT OUTSIDE OF THE U.S. GOVERNMENT WHILE PROVIDING REAL TIME HELP TO THOSE FACING THE DISEASE. SINCE ITS FOUNDING IN 1982, KOMEN HAS FUNDED nearly $1.1 BILLION IN BREAST CANCER RESEARCH IN MORE THAN 2700 GRANTS AND more than 500 CLINICAL TRIALS CONDUCTED BY THOUSANDS OF THE WORLD'S BEST AND BRIGHTEST RESEARCHERS ACROSS THE US AND AROUND THE WORLD. KOMEN HAS ALSO PROVIDED OVER $2.3 BILLION IN FUNDING FOR PATIENT NAVIGATION, SCREENING, DIAGNOSIS, TREATMENT, EDUCATION , ADVOCACY, AND PSYCHOSOCIAL SUPPORT PROGRAMS SERVING MILLIONS OF PEOPLE IN MORE THAN 60 COUNTRIES WORLDWIDE. KOMEN WAS FOUNDED BY NANCY G. BRINKER, WHO PROMISED HER SISTER, SUSAN G. KOMEN, THAT SHE WOULD END THE DISEASE THAT CLAIMED SUZY'S LIFE. WITH THIS INVESTMENT, KOMEN IS SUPPORTING LABORATORY RESEARCH, TRANSLATIONAL STUDIES, AND CLINICAL TRIALS THAT ARE PAVING THE ROAD WITH SCIENTIFIC DISCOVERIES THAT ARE: - UNRAVELLING THE BIOLOGY OF BREAST CANCER, - LEADING TO THE DEVELOPMENT OF NEW BREAST CANCER DRUGS, - DEVELOPMENT OF NEW TECHNOLOGIES AND TESTS, AND - NEW INTERVENTIONS THAT ARE CHANGING THE STANDARD OF BREAST CANCER CARE AND IMPROVING THE DELIVERY OF THAT CARE. OUR GOAL IS TO ADVANCE PERSONALIZED MEDICINE AND IMPROVE HEALTH OUTCOMES FOR EVERYONE. KOMEN HAS HAD MORE THAN 680 RESEARCH DISCOVERIES SINCE WE STARTED TRACKING THEM IN 2016 THAT ARE MOVING US CLOSER TO THAT GOAL. NEARLY TWO-THIRDS OF THESE DISCOVERIES FOCUS ON OUR RESEARCH PRIORITIES OF CONQUERING METASTATIC AND AGGRESSIVE BREAST CANCERS AND ELIMINATING BREAST CANCER DISPARITIES. THEY INCLUDE SUCH THINGS AS NEW BIOMARKERS, NEW DRUG TARGETS, NEW TREATMENTS, AND NEW HEALTHCARE DELIVERY TOOLS IN PAVING THIS ROAD WITH SCIENTIFIC DISCOVERIES, WE'RE ALSO PAVING IT WITH HOPE. THE HOPE THAT NEW WAYS TO DETECT, DIAGNOSE, TREAT, PREVENT AND, ULTIMATELY, CURE BREAST CANCER ARE AROUND THE CORNER. THERE WHEN PEOPLE WITH BREAST CANCER NEED THEM TO ALLOW THEM TO LIVE LONGER, WITH IMPROVED QUALITY OF LIFE. RESEARCH SINCE ITS FOUNDING IN 1982, KOMEN'S RESEARCH INVESTMENTS HAVE CONTRIBUTED TO MANY MAJOR ADVANCES IN BREAST CANCER SCIENCE. THE PROGRESS HAS BEEN SIGNIFICANT - TODAY, WE KNOW THAT BREAST CANCER IS MORE THAN A SINGLE DISEASE. WE HAVE A BETTER UNDERSTANDING OF THE GENETICS OF BREAST CANCER AND THE CRITICAL NEED TO TAILOR SCREENING, DIAGNOSIS, TREATMENT, AND PREVENTION STRATEGIES TO INDIVIDUALS THROUGH ADVANCES IN PRECISION MEDICINE. KOMEN'S RESEARCH PROGRAMS ARE FOCUSED ON BREAKTHROUGH RESEARCH TO PREVENT AND CURE BREAST CANCER THROUGH BETTER APPROACHES FOR EARLY DETECTION AND DIAGNOSIS, UNDERSTANDING METASTASIS AND RECURRENCE, DEVELOPING NOVEL THERAPIES FOR ALL STAGES OF BREAST CANCER, AND DEVELOPING NEW APPROACHES TO ADDRESS DISPARITIES IN BREAST CANCER OUTCOMES, WITH THE GOAL OF SUPPORTING WORK THAT HAS SIGNIFICANT POTENTIAL TO LEAD TO NEW TREATMENTS, TECHNOLOGIES AND INTERVENTIONS. KOMEN'S RESEARCH PROGRAMS ARE GUIDED BY 46 OF THE WORLD'S LEADERS IN BREAST CANCER RESEARCH, ONCOLOGY AND ADVOCACY. THE SCIENTIFIC ADVISORY BOARD ASSISTS KOMEN IN SETTING ITS RESEARCH STRATEGY AND PRIORITIZING ITS RESEARCH INVESTMENT. THE KOMEN SCHOLARS LEAD AND PARTICIPATE IN KOMEN'S WORLD-CLASS SCIENTIFIC PEER REVIEW PROCESS. OUR ADVOCATES IN SCIENCE BRING THE COLLECTIVE PATIENT VOICE TO KOMEN'S RESEARCH PROGRAMS AND SCIENTIFIC ACTIVITIES, EMPHASIZING URGENCY AND PATIENT IMPACT. THIS YEAR WE ANNOUNCED THE NEW CLASS OF SIX ESTEEMED BREAST CANCER RESEARCHERS AND TWO NEW PATIENT ADVOCATES TO THE KOMEN SCHOLARS. THESE WOMEN AND MEN JOIN AN EXCLUSIVE GROUP OF BREAST CANCER RESEARCHERS, CLINICIANS AND ADVOCATES WHO HELP GUIDE THE ORGANIZATION'S WORK TO SAVE LIVES AND END BREAST CANCER. KOMEN AWARDS GRANTS TO INDIVIDUAL SCIENTISTS, RESEARCH TEAMS, AND ORGANIZATIONS AROUND THE WORLD THROUGH A FAIR, TRANSPARENT, RIGOROUS, AND COMPETITIVE REVIEW PROCESS THAT ENSURES MAXIMUM IMPACT FOR OUR RESEARCH INVESTMENT. IN FY22, KOMEN AWARDED 48 GRANTS THROUGH ITS RESEARCH PROGRAMS TO SUPPORT SCIENTIFIC RESEARCH, IN THE UNITED STATES, AND CANADA. CAREER CATALYST RESEARCH GRANTS SUPPORT EARLY CAREER INVESTIGATORS CONDUCTING OUTSTANDING RESEARCH THAT WILL USE LIQUID BIOPSY TECHNOLOGY TO IMPROVE THE TREATMENT AND EARLY DETECTION OF METASTATIC BREAST CANCER. LEADERSHIP GRANTS SUPPORT KOMEN SCHOLARS PURSUING INNOVATIVE RESEARCH PROJECTS WHICH WILL IMPROVE THE UNDERSTANDING, DETECTION, TREATMENT OR PREVENTION OF BREAST CANCER, WITH A FOCUS ON CONQUERING METASTATIC BREAST CANCER AND ELIMINATING BREAST CANCER DISPARITIES. THE 48 RESEARCH GRANTS AWARDED IN FY22 ARE: CAREER CATALYST RESEARCH GRANTS: DANIEL HOLLERN, PH.D., OF SALK INSTITUTE FOR BIOLOGICAL STUDIES WILL IDENTIFY WAYS THAT METASTATIC TUMOR CELLS AVOID OR SUPPRESS THE IMMUNE SYSTEM'S B CELLS IN TRIPLE NEGATIVE BREAST CANCER (TNBC) PATIENTS, SPECIFICALLY PATIENTS THAT ALSO HAVE LIVER TUMORS. THE GOAL IS TO IMPROVE AN EXISTING TREATMENT CALLED ANTI-PDL1 THERAPY TO HELP BOOST B CELL ACTIVITY AND REDUCE MORTALITY IN TNBC PATIENTS WITH LIVER TUMORS. HARUKA ITAKURA, M.D., PH.D., OF STANFORD UNIVERSITY SCHOOL OF MEDICINE WILL CONDUCT A STUDY THAT WILL TAKE EXISTING MRI AND CT IMAGES COLLECTED FROM HER2+ BREAST CANCER PATIENTS AND USE ADVANCED DATA SCIENCE/AI TO IDENTIFY KEY FACTORS FOR PREDICTING FUTURE BRAIN METASTASIS. THE GOAL OF THIS STUDY IS TO USE NON-INVASIVE TECHNIQUES TO IDENTIFY PATIENTS WITH HER2+ BREAST CANCER WHO ARE ALSO AT RISK FOR DEVELOPING METASTATIC BRAIN TUMORS. MARIYA ROZENBLIT, M.D., OF YALE CANCER CENTER WILL CONDUCT A CLINICAL TRIAL TO EVALUATE VARIOUS THERAPIES OFFERED TO PATIENTS WITH STAGE 4 OLIGOMETASTATIC BREAST CANCER (OMBC) AND TO CREATE AN ONLINE PLATFORM THAT REGISTERS STAGE 4 OMBC PATIENTS, STANDARDIZES THE TREATMENT APPROACH AND ENABLES FOLLOW-UP DATA COLLECTION. DR. ROZENBLIT HOPES THIS COLLECTED DATA WILL DEMONSTRATE HOW THESE TREATMENT OPTIONS MAY PROMOTE LONG-TERM SURVIVAL AND FUTURE PREVENTION OF METASTATIC BREAST CANCER FOR THESE PATIENTS. TARAH BALLINGER, M.D., OF INDIANA UNIVERSITY WILL PILOT A 16-WEEK EXERCISE INTERVENTION FOR METASTATIC BREAST CANCER (MBC) PATIENTS TO DETERMINE WHETHER THE ADDITION OF EXERCISE TO THEIR COMPREHENSIVE CARE PLAN COULD IMPROVE LONG-TERM TREATMENT OUTCOMES. MARIA SOSA, PH.D., OF ICHAN SCHOOL OF MEDICINE WILL STUDY THE EFFECTIVENESS OF A NEW PROPOSED DRUG THERAPY THAT WILL BLOCK THE ACTIVITY OF ZFP296, A PROTEIN THAT IS BELIEVED TO PROMOTE TUMOR CELL GROWTH AND METASTASIS. PEDRAM RAZAVI, M.D., PH.D., OF MEMORIAL SLOAN KETTERING CANCER CENTER WILL ANALYZE CIRCULATING TUMOR CELL DNA (CTDNA) FROM EARLY-STAGE, HIGH RISK PATIENTS TO DETECT EARLY BREAST CANCER METASTASES OR ANY REMAINING BREAST CANCER CELLS AFTER TREATMENT (MINIMAL RESIDUAL DISEASE, OR MRD). DR. RAZAVI WILL USE THIS CTDNA TO IDENTIFY PERSONALIZED TREATMENTS FOR PATIENTS AT RISK FOR DEVELOPING MRD OR TREATMENT RESISTANCE, WITH THE ULTIMATE GOAL OF DECREASING THE RISK OF METASTATIC RECURRENCE AND MORTALITY. HAI WANG, PH.D., OF ROSWELL PARK CANCER INSTITUTE WILL STUDY BREAST CANCER CELL METASTASIS TO THE BONE AND THE METABOLIC CHANGES THESE METASTATIC CELLS GO THROUGH TO GROW IN THE BONE VERSUS THE PRIMARY TUMOR LOCATION IN THE BREAST. DR. WANG WILL INVESTIGATE HOW BREAST CANCER TUMOR CELLS THAT METASTASIZE TO THE BONE SWITCH THEIR SOURCE OF METABOLIC ENERGY PRODUCTION AND AIMS TO USE THESE FINDINGS TO EXPLORE NEW TREATMENT STRATEGIES THAT COULD IMPROVE SURVIVAL RATES FOR METASTATIC BREAST CANCER PATIENTS. Form 990, Part III, Line 4 Program service accomplishments continued SONYA REID, M.D., M.P.H., OF VANDERBILT UNIVERSITY WILL CONDUCT A CLINICAL TRIAL FOR PATIENTS WITH HORMONE RECEPTOR-POSITIVE (HR+, HER2-) METASTATIC BREAST CANCER (MBC) TO DETERMINE WHETHER A GENE PANEL TEST FOR GENETIC VARIATIONS IN HR+, HER2- MBC COULD INFORM MORE EFFECTIVE TREATMENT STRATEGIES, ESPECIALLY FOR BREAST CANCER TYPES THAT ARE MORE PREVALENT IN RACIAL/ETHNIC MINORITIES. THE GOAL OF THIS PROJECT IS TO CHARACTERIZE THE IMPACT OF GENETIC VARIATION ON MBC SURVIVAL AND DISPARATE OUTCOMES, AND TO DEVELOP MORE PERSONALIZED TREATMENTS THAT COULD IMPACT CLINICAL OUTCOMES AMONG A RACIALLY DIVERSE PATIENT POPULATION. SRINIVAS MALLADI, PH.D., OF THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER WILL STUDY AND TARGET DORMANT BREAST CANCER CELLS TO PREVENT THEM FROM RECURRING AND METASTASIZING TO THE BRAIN AND INTERACTING WITH BRAIN CELLS CALLED ASTROCYTES. BY ANALYZING HOW ASTROCYTES NOURISH NEIGHBORING BREAST CANCER CELLS IN THE BRAIN WITH FATTY ACIDS, THE GOAL IS TO EVALUATE THE IMPACT OF TARGETING THE CREATION OF THESE FATTY ACIDS TO PREVENT METASTATIC RECURRENCE. LEADERSHIP GRANTS: MELINDA TELLI, M.D., OF STANFORD UNIVERSITY WILL CONDUCT TWO CLINICAL TRIALS USING LIQUID BIOPSY TO TEST FOR CIRCULATING TUMOR DNA, AN INDICATOR OF RISK FOR RELAPSE IN PATIENTS WITH TRIPLE NEGATIVE BREAST CANCER (TNBC). THE HOPE IS THAT THIS LIQUID BIOPSY TECHNIQUE CAN BE USED TO MONITOR PATIENTS WHO ARE AT HIGHER RISK FOR A TNBC RELAPSE AND ALLOW FOR BETTER, MORE PERSONALIZED TREATMENTS. LAJOS PUSZTAI, M.D., OF YALE CANCER CENTER WILL TEST AN INNOVATIVE NEW TOOL FOR MEASURING TUMOR GROWTH, A NEW BIOMARKER FOR TRIPLE NEGATIVE BREAST CANCER (TNBC) TREATMENT GUIDANCE AND A NEW ANTI-CANCER THERAPY TARGETING CANCER METABOLISM. DR. PUSZTAI HOPES TO IMPROVE TNBC OUTCOMES AND PREVENT RECURRENCE OF METASTATIC TUMORS THROUGH THIS WORK. JULIE PALMER, SC.D., M.P.H., OF BOSTON UNIVERSITY WILL CONDUCT A STUDY THAT WILL USE TUMOR SAMPLES AND PSYCHOSOCIAL STRESS DATA FROM WOMEN ENROLLED IN THE BLACK WOMEN'S HEALTH STUDY TO DEMONSTRATE HOW PSYCHOSOCIAL STRESS IMPACTS BREAST CANCER BIOLOGY AND OUTCOMES. THE GOAL OF THIS PROJECT IS TO UNDERSTAND HOW PSYCHOSOCIAL STRESS INFLUENCES BREAST CANCER AND TO IDENTIFY POTENTIAL INTERVENTIONS TO REDUCE PSYCHOSOCIAL STRESS, AND TO REDUCE DISPARITIES IN BREAST CANCER MORTALITY FOR BLACK WOMEN. KOMEN SCIENTIFIC ADVISORY BOARD MEMBER KORNELIA POLYAK, M.D., PH.D., OF DANA FARBER CANCER INSTITUTE WILL DETERMINE HOW THE SIGNALING OF THE PROTEIN TRANSFORMING GROWTH FACTOR BETA (TGF) MAY CONTRIBUTE TO EARLY BREAST CANCER DEVELOPMENT, INCLUDING A SMALL MUTATION THAT IS MORE PREVALENT IN AFRICAN AMERICAN WOMEN. THIS RESEARCH WILL HELP TO IDENTIFY AT-RISK POPULATIONS AND POTENTIAL THERAPEUTIC TARGETS, WITH THE GOAL OF BETTER UNDERSTANDING AND ENDING BREAST CANCER HEALTH DISPARITIES AMONG AFRICAN AMERICAN WOMEN. YIBIN KANG, PH.D., OF PRINCETON UNIVERSITY WILL INVESTIGATE WHETHER THE ENZYME ALDH1A2 COULD BE A THERAPEUTIC TARGET FOR PREVENTING BREAST CANCER PROGRESSION. THE GOAL OF THIS RESEARCH IS TO BETTER UNDERSTAND THE IMMUNE SYSTEM'S IMPACT ON BREAST CANCER DEVELOPMENT AND TREATMENT WHILE ALSO EXPLORING THE THERAPEUTIC POTENTIAL OF ALDH1A2 AS A NEW TARGET TO ELIMINATE BREAST TUMORS AND METASTASIS. SOHRAB SHAH, PH.D., OF MEMORIAL SLOAN-KETTERING CANCER CENTER WILL PERFORM A STUDY USING TRIPLE-NEGATIVE BREAST CANCER (TNBC) TUMOR DNA AND LIQUID BIOPSY SAMPLES TO OBSERVE HOW IMMUNE CELLS AND TUMOR DNA MUTATIONS CAN EVOLVE OVER TIME WITH TREATMENT OR DISEASE PROGRESSION. THE GOAL OF THIS PROJECT IS TO DEVELOP A PREDICTIVE MODEL THAT CAN IDENTIFY THE OPTIMAL TIMEFRAME FOR INTERVENTION AFTER NEOADJUVANT CHEMOTHERAPY FOR TNBC PATIENTS THAT ARE AT THE HIGHEST RISK OF RELAPSE. STEFFI OESTERREICH, PH.D., OF UNIVERSITY OF PITTSBURGH WILL UNCOVER THE EVOLUTION OF ESTROGEN RECEPTOR POSITIVE (ER+) PRIMARY CANCER TO METASTATIC RECURRENCE USING TISSUE SAMPLES AND LIQUID BIOPSY, AND TO CREATE GUIDELINES FOR A RAPID AUTOPSY PROGRAM TO BETTER UNDERSTAND METASTATIC DISEASE. THIS WORK WILL CREATE RICH DATASETS FOR OTHER RESEARCHERS AND UNCOVER BETTER TREATMENT OPTIONS FOR PREVENTING THE RECURRENCE OF METASTATIC TUMORS. AMELIE RAMIREZ, DR.P.H., M.P.H., OF THE UNIVERSITY OF TEXAS HEALTH SCIENCES CENTER AT SAN ANTONIO WILL STUDY THE IMPACT OF A CULTURALLY ADAPTED, HOLISTIC BREAST CANCER SURVIVORSHIP PROGRAM ON LATINA BREAST CANCER SURVIVORS THAT INCLUDES YOGA, MEDITATION AND DIETARY GUIDANCE. THE GOAL OF THIS PROJECT IS TO IDENTIFY WHETHER A HOLISTIC SURVIVORSHIP PROGRAM CAN IMPROVE THE QUALITY OF LIFE AND HEALTH OUTCOMES FOR LATINA BREAST CANCER SURVIVORS. ALANA WELM, PH.D., OF THE UNIVERSITY OF UTAH WILL RESEARCH A MOLECULE CALLED SHORT FORM OF RON (SFRON) THAT IS CURRENTLY BEING STUDIED IN CLINICAL TRIALS AS A THERAPEUTIC TARGET TO BLOCK BREAST CANCER TUMOR AND METASTASIS GROWTH. DR. WELM WILL STUDY SFRON TO DETERMINE HOW IT FUNCTIONS IN METASTASIS, AND THE ANTI-TUMOR IMMUNE RESPONSE OF THE BODY. THE GOAL OF THIS PROJECT IS TO IDENTIFY HOW SFRON AND THE IMMUNE SYSTEM MAY BE HARNESSED TO DEVELOP MORE EFFECTIVE TREATMENTS FOR PATIENTS WITH METASTATIC BREAST CANCER. LEADERSHIP GRANTS - NEW KOMEN SCHOLARS: ALLISON KURIAN, M.D., OF STANFORD UNIVERSITY WILL TEST AN ETHNICALLY DIVERSE STUDY GROUP OF PATIENTS USING A NEW LIQUID BIOPSY TECHNIQUE THAT CAN DETECT PRIMARY AND RECURRENT BREAST CANCER AT AN EARLIER STAGE USING LESS GENETIC MATERIAL. THE GOAL OF THIS PROJECT IS TO IDENTIFY WHICH PATIENT POPULATIONS COULD BENEFIT FROM EARLIER BREAST CANCER DETECTION USING THIS NEW STRATEGY. SUNIL BADVE, M.D., FRCPATH, OF EMORY UNIVERSITY WILL STUDY THE STRUCTURAL DIVERSITY OF BREAST CANCER PATIENT TUMOR CELLS AND THEIR RESISTANCE TO TREATMENTS THAT USE CDK 4/6 INHIBITORS, AND TO USE THIS DATA TO DEVELOP NEW THERAPEUTIC STRATEGIES TO PREVENT RESISTANCE AND RECURRENCE NANCY LIN, M.D., OF DANA FARBER CANCER INSTITUTE WILL EXPLORE WAYS TO IMPROVE THE EFFECTIVENESS OF ANTIBODY-DRUG CONJUGATES FOR PATIENTS WITH METASTATIC BREAST CANCER (MBC). BY USING TISSUE AND PLASMA SAMPLES FROM PATIENTS TREATED WITH THESE DRUGS, DR. LIN AIMS TO UNCOVER HOW TO PREVENT RESISTANCE TO THESE THERAPIES OVER TIME AND IMPROVE LONG-TERM TREATMENT OUTCOMES FOR MBC PATIENTS. SARA M. TOLANEY, M.D., M.P.H., OF DANA FARBER CANCER INSTITUTE WILL TEST THE ABILITY OF AN ANTIBODY-DRUG CONJUGATE DRUG CALLED SACITUZUMAB GOVITECAN (SG) TO INCREASE RESPONSIVENESS TO PEMBROLIZUMAB TREATMENT IN METASTATIC TRIPLE NEGATIVE BREAST CANCER AND HR+/HER2- METASTATIC BREAST CANCER PATIENTS. THIS RESEARCH WILL HELP DETERMINE WHETHER COMBINATION THERAPY USING BOTH SG AND PEMBROLIZUMAB COULD IMPROVE LONG-TERM SURVIVAL OUTCOMES FOR MBC PATIENTS. CYNTHIA MA, M.D., PH.D., OF WASHINGTON UNIVERSITY WILL PERFORM A STUDY USING PATIENT TUMOR SAMPLES COLLECTED POST-SURGERY AND FOLLOWING ENDOCRINE THERAPY TO IDENTIFY GENETIC CHANGES AND MECHANISMS OF ENDOCRINE RESISTANCE. DR. MA HOPES THAT THIS DATA WILL HELP TO IDENTIFY WHICH PATIENTS MAY DEVELOP RESISTANCE TO ENDOCRINE THERAPY AND GUIDE THE DEVELOPMENT OF MORE PERSONALIZED TREATMENTS THAT WILL SAVE LIVES. JORGE REIS-FILHO, M.D., PH.D., FRCPATH, OF MEMORIAL SLOAN-KETTERING CANCER CENTER WILL INVESTIGATE HOW DEFECTS TO DNA REPAIR PROCESSES CAUSE INCREASED INSTABILITY AND RESISTANCE TO ANTI-ESTROGEN THERAPY IN ESTROGEN RECEPTOR POSITIVE (ER+) BREAST CANCER CELLS. THIS RESEARCH WILL PROVIDE VALUABLE INSIGHT INTO THE EVOLUTION OF THERAPEUTIC RESISTANCE OF ER+ BREAST CANCER CELLS THAT CAN BE USED FOR FUTURE DEVELOPMENT OF MORE EFFECTIVE TREATMENTS. SCIENTIFIC ADVISORY BOARD MEMBER ADRIAN LEE, PH.D., OF THE UNIVERSITY OF PITTSBURGH WILL DEVELOP AND CHARACTERIZE A LIVING BIOBANK FROM VARIOUS NORMAL AND BREAST CANCER SPECIMENS DERIVED FROM PATIENT SAMPLES. THIS BIOBANK WILL SERVE AS A PUBLIC RESOURCE FOR RESEARCHERS WITH A FOCUS ON DIVERSITY IN RACE (ANCESTRY) AND BREAST CANCER SUBTYPES AND WILL ACCELERATE RESEARCH LEADING TO NEW INSIGHTS IN DRUG RESISTANCE AND PROGRESSION, NEW THERAPEUTIC TARGETS, AND IMPROVED CLINICAL OUTCOMES. ANGELA DEMICHELE, M.D., M.S.C.E., OF THE UNIVERSITY OF PENNSYLVANIA WILL INVESTIGATE MINIMAL RESIDUAL DISEASE AND DORMANT TUMOR CELLS BY USING NEW ASSAYS TO DETECT DISSEMINATED TUMOR CELLS AND CTDNA IN PATIENT TUMOR AND BLOOD SAMPLES. SHE WILL IDENTIFY AT-RISK PATIENTS, DIFFERENTIATE BETWEEN DORMANT AND REACTIVATED BREAST CANCER CELLS, AND MORE ACCURATELY EVALUATE THE IMPACT OF TREATMENTS ON DORMANT CELLS, WITH THE GOAL OF PREVENTING METASTATIC BREAST CANCER RECURRENCE AND DEATH AND IMPROVING THE QUALITY OF LIFE FOR SURVIVORS. Form 990, Part III, Line 4 Program service accomplishments continued MARIANA CHAVEZ MACGREGOR, M.D., M.SC., FASCO, OF THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER WILL STUDY THE SOCIAL AND POLICY-LEVEL FACTORS THAT AFFECT BREAST CANCER PATIENTS FROM UNDERSERVED POPULATIONS WHO FREQUENTLY ENCOUNTER MORE BARRIERS TO SUCCESSFUL TREATMENT THAN OTHER PATIENTS. THE GOAL IS TO IDENTIFY WHAT FACTORS CREATE THESE DISPARITIES AND DEVELOP STRATEGIES THAT WILL STRENGTHEN THE QUALITY OF CARE AND IMPROVE TREATMENT OUTCOMES FOR UNDERSERVED PATIENTS. MBC COLLABORATIVE RESEARCH INITIATIVE MELISSA TROESTER M.D., PH.D. AND TERRY HYSLOP PH.D. ARE COLLABORATING ON A PROPOSAL TO LEVERAGE HIGH QUALITY, INDIVIDUAL-LEVEL TUMOR BIOLOGY AND SOCIAL DETERMINANTS OF HEALTH DATA IN THE CAROLINA BREAST CANCER STUDY (CBCS) DATA TOGETHER WITH COMMUNITY-LEVEL VARIABLES TO EVALUATE HOW STRESS CONTRIBUTES TO HIGHER METASTASIS AND WORSE BREAST CANCER OUTCOMES IN BLACK WOMEN WHEN COMPARED TO WHITE WOMEN. ZACH HARTMAN PH.D. AND BENJAMIN VINCENT M.D. WILL WORK TOGETHER ON A PROPOSAL TO DETERMINE HOW TO MAKE METASTATIC TRIPLE-NEGATIVE BREAST CANCERS MORE SENSITIVE TO IMMUNOTHERAPIES. THE COLLABORATORS PROPOSE A METHOD OF STIMULATING THE ANTI-TUMOR RESPONSE WITH VACCINE TECHNOLOGIES TO INDUCE A SUSTAINABLE, ROBUST, AND BROAD STIMULUS TO THE INNATE IMMUNE SYSTEM THAT WILL BE TESTED FOR THE ABILITY TO ELIMINATE DISTANT METASTASIS. JENIFER FREEDMAN PH.D., STEVEN PATIERNO PH.D., AND KATIE HOADLEY, PH.D. ARE COLLABORATING TO INVESTIGATE DIFFERENCES IN BREAST CANCER OUTCOME BY RACE AS BLACK WOMEN SUFFER DISPROPORTIONATELY AND WITH OFTEN A WORSE PROGNOSIS. THE STUDY LEADERS IDENTIFIED BIOLOGICAL DIFFERENCES IN CANCER BETWEEN AFRICAN AND EUROPEAN ANCESTRY THAT RESULTED FROM A PROCESS CALLED SPLICING. THE RESEARCHERS IN THIS PROPOSAL SEEK TO DETERMINE IF THESE DIFFERENCES CAUSE BREAST CANCER CELLS TO GROW AND SPREAD MORE QUICKLY. OPPORTUNITY GRANTS: MONICA M. BERTAGNOLLI, M.D., OF THE ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY WILL RECEIVE $249,429 TO PERFORM A GENOMIC ANALYSIS OF PAIRED GERMLINE AND PRE-TREATMENT TUMOR SAMPLES FROM POSTMENOPAUSAL WOMEN WITH STAGE 2 AND 3 ER+/HER2-NEGATIVE (HER2-) BREAST CANCER COLLECTED THROUGH THE ALTERNATE TRIAL. THE GOAL IS TO ESTIMATE THE EFFECT OF GENE MUTATIONS ON ENDOCRINE THERAPY RESISTANCE, DEVELOP BIOMARKER TESTS TO DETECT RESIDUAL DISEASE AND ADVANCE PRECISION MEDICINE CAPABILITIES IN THE FIELD OF ER+ BREAST CANCER. ETTA D. PISANO, M.D., OF THE ECOG-ACRIN CANCER RESEARCH GROUP WILL BE AWARDED $247,248 TO IMPLEMENT WAYS TO IMPROVE AFRICAN-AMERICAN PARTICIPATION IN THE TOMOSYNTHESIS MAMMOGRAPHIC IMAGING SCREENING TRIAL (TMIST) BIOSPECIMEN SUB-STUDY THROUGH THE DEVELOPMENT AND DISSEMINATION OF EDUCATIONAL MATERIALS HIGHLIGHTING THE IMPORTANCE OF PARTICIPATION IN BIOSPECIMEN RESEARCH. THIS PROJECT WILL INCREASE THE DIVERSITY OF PATIENT SAMPLES IN THE EXISTING BIOBANK THAT WILL BE USED TO SUPPORT FUTURE STUDIES FOCUSED ON BREAST CANCER SCREENING, DIAGNOSIS, AND TREATMENT INTERVENTIONS. NADINE M. TUNG, M.D., OF THE ECOG-ACRIN CANCER RESEARCH GROUP WILL BE AWARDED $249,256 TO EXPAND RESEARCH QUESTIONS IN THE COMPASSHER2 PCR TRIAL TO DETERMINE WHETHER UNIQUE BIOMARKERS IDENTIFIED IN STAGE 2 OR 3 HER2-POSITIVE (HER2+) BREAST CANCER PATIENT TUMOR SAMPLES CAN BE USED TO PREDICT OUTCOMES OF PRE-SURGERY THERAPY. THE GOAL OF THIS PROJECT IS TO PROVIDE DATA THAT CAN BE USED TO PERSONALIZE TREATMENT DECISIONS, IMPROVE QUALITY OF LIFE, AND OPTIMIZE TREATMENTS FOR PATIENTS DIAGNOSED WITH HER2+ BREAST CANCER. ANNA MARIA V. STORNIOLO, M.D., OF INDIANA UNIVERSITY (IU) WILL RECEIVE TWO OPPORTUNITY GRANTS TOTALING $1,803,000 TO SUPPORT THE SUSAN G. KOMEN TISSUE BANK (KTB) AT THE IU SIMON CANCER CENTER, THE WORLD'S ONLY BIOREPOSITORY OF NORMAL BREAST TISSUE. THESE GRANTS SUPPORT THE COLLECTION AND STORAGE OF BIOSAMPLES, INCLUDING WHOLE BLOOD, DNA, SERUM, PLASMA, AND HEALTHY BREAST TISSUE FROM WOMEN NOT KNOWN TO HAVE BREAST CANCER, AS WELL AS THE DISTRIBUTION OF THE SAMPLES TO RESEARCHERS WORLDWIDE. ACCESS TO THESE NORMAL TISSUE SAMPLES PROVIDE RESEARCHERS THE OPPORTUNITY TO UNDERSTAND THE CHANGES THAT HAPPEN IN A NORMAL BREAST AND HOW THESE MOLECULAR MECHANISMS ARE ALTERED IN THE MALIGNANT PROCESS. EDUCATION KOMEN IS A TRUSTED SOURCE OF BREAST CANCER INFORMATION FOR PEOPLE ALL OVER THE WORLD AND IS INSTRUMENTAL IN CONNECTING PEOPLE WITH THE RESOURCES THEY NEED IN THEIR FIGHT AGAINST BREAST CANCER. OUR WEBSITE, KOMEN.ORG, PROVIDES CURRENT, SAFE, ACCURATE, COMPREHENSIVE, AND UNBIASED INFORMATION ABOUT BREAST CANCER, BASED ON SCIENTIFIC EVIDENCE. CONTENT IS OFFERED IN A VARIETY OF FORMATS INCLUDING INTERACTIVE VIDEO USING ANIMATION AND VOICEOVER IN ENGLISH AND SPANISH, ILLUSTRATIONS, CHARTS, GRAPHS, AND SHORT VIDEOS TO MEET THE LEARNING PREFERENCES AND NEEDS OF OUR WEB VISITORS. THE ABOUT BREAST CANCER AND PORTIONS OF THE PATIENT & CAREGIVER SECTIONS OF KOMEN'S WEBSITE, CO-DEVELOPED WITH HARVARD MEDICAL SCHOOL FACULTY AND DANA-FARBER CANCER INSTITUTE STAFF, RECEIVED NEARLY 3 MILLION PAGE VIEWS DURING FY22. KOMEN LAUNCHED THE CLINICAL TRIALS INITIATIVE ON KOMEN.ORG WITH THE GOAL OF EDUCATING PEOPLE ABOUT THE ROLE CLINICAL TRIALS, INCLUDING THOSE FROM UNDER- REPRESENTED POPULATIONS, AND EMPOWERING PEOPLE WITH INFORMATION ON TRIALS AND RESOURCES, INCLUDING OUR CLINIAL TRIALS HELPLINE. THE RESOURCES HELP TO ENSURE PATIENTS ARE EQUIPPED TO MAKE INFORMED DECISIONS REGARDING TRIAL PARTICIPATION IN PARTNERSHIP WITH THEIR HEALTH CARE PROVIDERS. THE INITIATIVE ALSO RAISES AWARENESS OF THE DIFFERENT TYPES OF TRIALS, INCLUDING TRIALS SUPPORTED BY KOMEN, FOCUSED ON RISK, SCREENING AND EARLY DETECTION, TREATMENT, FAMILY SUPPORT, QUALITY OF LIFE AND SURVIVORSHIP. KOMEN ALSO PROVIDES EVIDENCE-BASED, EASY-TO-READ EDUCATIONAL MATERIALS IN DOWNLOADABLE FORMATS ON KOMEN.ORG. EXAMPLES OF KOMEN EDUCATIONAL MATERIALS INCLUDE: A) BREAST SELF-AWARENESS MESSAGE CARDS IN MORE THAN 40 LANGUAGES, B) BREAST CANCER SPECIFIC BROCHURES AND FACTSHEETS, C) BOOKLETS WITH SUPPORT INFORMATION FOR SURVIVORS AND CO-SURVIVORS, AND D) TOOLKITS FOR BREAST CANCER OUTREACH AND EDUCATION FOR HISPANIC/LATINO IN ENGLISH AND SPANISH, FOR BLACK AND AFRICAN AMERICAN COMMUNITIES AND FOR LESBIANS, BISEXUAL WOMEN AND TRANSGENDER AND QUESTIONING/QUEER PEOPLE. IN ADDITION, IN FY22 KOMEN CONTINUED TO SUPPORT THE METASTATIC BREAST CANCER (MBC) COMMUNITY BY HOSTING 25 VIRTUAL EVENTS THROUGH THE MBC IMPACT SERIES. THESE EVENTS PROVIDED PEOPLE LIVING WITH METASTATIC BREAST CANCER AND THEIR LOVED ONES A SAFE, COLLABORATIVE SPACE TO GATHER INFORMATION AND DISCOVER PRACTICAL RESOURCES TO HELP MAKE DECISIONS FOR IMPROVED PHYSICAL AND EMOTIONAL HEALTH. PATIENT SUPPORT AT KOMEN, WE ARE FOCUSED ON SAVING LIVES BY REMOVING BARRIERS AND ENSURING ALL PEOPLE RECEIVE THE CARE THEY NEED THROUGH KOMEN'S PATIENT CARE CENTER. OFFICIALLY LAUNCHED IN FY22, THE KOMEN PATIENT CARE CENTER IS A SUITE OF INTEGRATED DIRECT PATIENT PROGRAMS THAT ENSURE NO ONE FACES BREAST CANCER ALONE. THE PATIENT CARE CENTER PROGRAMS AND SERVICES INCLUDE THE BREAST CARE HELPLINE, SCREENING & DIAGNOSTICS PROGRAM, FINANCIAL ASSISTANCE PROGRAM, AND PATIENT NAVIGATION, ALL OF WHICH PROVIDE SUPPORT AND RESOURCES FOR PEOPLE IN LOCAL COMMUNITIES ACROSS THE COUNTRY. KOMEN'S PROGRAMS AND SERVICES REMOVE BARRIERS TO CARE AND WORK SEAMLESSLY TOGETHER SO A PERSON CAN ACCESS ALL THE PROGRAMS THROUGH ONE CENTRAL SOURCE. THE OVERARCHING GOAL OF OUR PATIENT CARE CENTER IS TO SAVE LIVES BY ENSURING PATIENTS STAY IN THE BREAST CANCER CONTINUUM OF CARE, OVERCOME BARRIERS AND CHALLENGES TO HIGH-QUALITY BREAST CARE SERVICES, COMPLETE TREATMENT, AND HAVE A HIGH QUALITY OF LIFE AND IMPROVED LONG-TERM OUTCOMES. THE PATIENT CARE CENTER SERVED ALMOST 27,000 PEOPLE IN FY22. METASTATIC BREAST CANCER COLLABORATIVE RESEARCH INITIATIVE KOMEN LAUNCHED THE METASTATIC BREAST CANCER COLLABORATIVE RESEARCH INITIATIVE (MBCCRI) WITH A PILOT PROGRAM AT DUKE UNIVERSITY AND THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL. THE GOAL IS TO CATALYZE AND SUPPORT MULTI-INSTITUTIONAL RESEARCH COLLABORATIONS AND BRING TOGETHER THE BEST AND BRIGHTEST RESEARCHERS AT SELECT INSTITUTIONS TO SHARE IDEAS, EXPERTISE AND RESOURCES. KOMEN WILL SUPPORT RESEARCH GRANT TO FIND BREAKTHROUGH DISCOVERIES TO END METASTATIC BREAST CANCER. Form 990, Part III, Line 4 Program service accomplishments continued INFLAMMATORY BREAST CANCER COLLABORATIVE FOR THE FIRST TIME, KOMEN IS LEADING TO DRIVE A NEW DIAGNOSTIC DEFINITION OF BREAST CANCER, SPECIFICALLY INFLAMMATORY BREAST CANCER, A DEADLY AND AGGRESSIVE FORM OF CANCER. KOMEN HAS PARTNERED WITH THE INFLAMMATORY BREAST CANCER RESEARCH FOUNDATION AND THE MILBURN FOUNDATION TO CONVENE PATIENT ADVOCATES, BREAST CANCER RESEARCHERS AND CLINICIANS TO REVIEW THE STATE OF IBC CARE AND RESEARCH GLOBALLY AND PROPOSE SPECIFIC INITIATIVES TO MOVE THE FIELD FORWARD. THE OUTCOME OF THE DISCUSSIONS WAS ABUNDANTLY CLEAR: THE FIELD NEEDS A FORMAL DEFINITION OF IBC. WITHOUT A CLEAR DEFINITION, BOTH PATIENT CARE AND RESEARCH SUFFER. DIAGNOSIS REMAINS SUBJECTIVE AND TREATMENT VARIABLE. THE GOAL IS TO MOVE BEYOND THE SUBJECTIVE 'CLINICAL DIAGNOSIS' TO A SET OF SPECIFIC DIAGNOSTIC CRITERIA AND SCORING SYSTEM THAT WILL ADVANCE IBC RESEARCH AND FACILITATE THE DISCOVERIES THAT WILL IMPROVE CARE OF IBC PATIENTS. A PROPOSED DEFINITION OF IBC, BASED ON A REVIEW OF CLINICAL, AND PATHOLOGIC FEATURES WAS SUBMITTED FOR PUBLICATION. BIG DATA FOR BREAST CANCER KOMEN CONTINUES WORK ON THE BIG DATA FOR BREAST CANCER INITIATIVE, WHICH IS AIMED AT USING BIG DATA TO FUEL SCIENTIFIC DISCOVERIES AND ACCELERATE THE DELIVERY OF EQUITABLE, PATIENT-FOCUSED CARE. KOMEN EMPOWERS BREAST CANCER PATIENTS, ADVOCATES AND THE PUBLIC WITH INFORMATION AND TOOLS TO MAKE DATA SHARING UNDERSTANDABLE THROUGH THE BIG DATA FOR BREAST CANCER PATIENTS EDUCATIONAL PROGRAMS. WE ALSO ADDRESS THE CHALLENGES OF INCORPORATING BIG DATA APPLICATIONS INTO BREAST CANCER RESEARCH AND CLINICAL CARE THROUGH WORKING WITH PARTNERS REPRESENTING A VARIETY OF STAKEHOLDERS IN BREAST CANCER RESEARCH. ADDITIONALLY, KOMEN SUPPORTS DATA SCIENCE PROJECTS TO IMPROVE BREAST CANCER OUTCOMES AND SAVE LIVES. PUBLIC POLICY AND ADVOCACY SUSAN G. KOMEN IS THE NONPARTISAN VOICE OF MORE THAN 3.8 MILLION BREAST CANCER SURVIVORS, THOSE LIVING WITH THE DISEASE AND THE PEOPLE WHO LOVE THEM. KOMEN WORKS TO EDUCATE PEOPLE ABOUT PUBLIC POLICY ISSUES, SO THEY ARE EMPOWERED TO BECOME FORCEFUL ADVOCATES FOR THEMSELVES AND THEIR NEIGHBORS, AND THEN UNITES THEIR COLLECTIVE VOICES FOR MAXIMUM IMPACT. THROUGH OUR CENTER FOR PUBLIC POLICY, KOMEN ENSURES THAT OUR POLICYMAKERS ARE EDUCATED ABOUT THE NEEDS OF BREAST CANCER PATIENTS AND PRIORITIZE THE ISSUES IMPACTING THEM. ONLY THROUGH INFORMED GOVERNMENT ACTION CAN WE MAKE THE BROAD, SYSTEMIC AND LASTING CHANGE REQUIRED. KOMEN'S 2021-2022 PUBLIC POLICY AND ADVOCACY PRIORITIES INCLUDED: EXPANDING ACCESS TO AFFORDABLE, HIGH-QUALITY HEALTH CARE FOR ALL PATIENT POPULATIONS; SUPPORTING INCREASED STATE AND FEDERAL FUNDING FOR BREAST CANCER RESEARCH AND INCREASED EDUCATION, UTLIZATION OF AND ACCESS TO CLINICAL TRIALS; SUPPORTING STATE AND FEDERAL FUNDING FOR THE CENTERS FOR DISEASE CONTROL AND PREVENTION'S (CDC) NATIONAL BREAST AND CERVICAL CANCER EARLY DETECTION PROGRAM (NBCCEDP); ADVOCATING FOR STATE AND FEDERAL POLICIES TO IMPROVE INSURANCE COVERAGE OF BREAST CANCER TREATMENTS, INCLUDING THOSE THAT WOULD REQUIRE ORAL PARITY, PRECLUDE SPECIALTY TIERS AND PREVENT STEP THERAPY PROTOCOLS; AND ADVOCATING FOR STATE AND FEDERAL POLICIES TO REDUCE OR ELIMINATE OUT-OF-POCKET COSTS FOR MEDICALLY NECESSARY DIAGNOSTIC IMAGING. IN ADDITION TO THE STATE AND FEDERAL WORK ON OUR PUBLIC POLICY AND ADVOCACY PRIORITIES, KOMEN ALSO ENGAGED ON ISSUES RELATED TO CUSTOM BREAST PROTHESES, GENETIC AND GENOMIC TESTING, LYMPHEDEMA, MEDICARE WAITING PERIODS, PALLIATIVE CARE, SURPRISE MEDICAL BILLING AND SURVIVORSHIP. KOMEN DEVELOPED AND IMPLEMENTED ADVOCACY CAMPAIGNS TO ENCOURAGE LAWMAKERS AND AGENCY OFFICIALS TO SUPPORT AND IMPLEMENT PROGRAMS THAT WOULD ADVANCE OUR PRIORITY ISSUES. KOMEN CONTINUED TO RECRUIT AND ENGAGE ADVOCATES TO FURTHER STRENGTHEN ITS GRASSROOTS ADVOCACY NETWORK. Form 990, Part VI, Line 1a Executive Committee THE ORGANIZATION'S BYLAWS PROVIDE FOR AN EXECUTIVE COMMITTEE COMPRISED OF A MINIMUM OF FIVE MEMBERS INCLUDING THE BOARD CHAIR, THE PRESIDENT AND CHIEF EXECUTIVE OFFICER, AND ADDITIONAL BOARD MEMBERS, AS RECOMMENDED BY THE GOVERNANCE COMMITTEE AND APPOINTED BY THE BOARD OF DIRECTORS. MEMBERS OF THE EXECUTIVE COMMITTEE MUST EITHER BE DIRECTORS OF THE ORGANIZATION OR THE PRESIDENT AND CHIEF EXECUTIVE OFFICER. THE BYLAWS PROVIDE THE EXECUTIVE COMMITTEE WITH THE AUTHORITY TO: (A) APPOINT MEMBERS TO NON-STANDING COMMITTEES OF THE ORGANIZATION, AND NAME CHAIRS OF SUCH COMMITTEES; (B) AUTHORIZE UNBUDGETED DISBURSEMENTS BY THE ORGANIZATION IN ACCORDANCE WITH THE SPECIFIC EXPENDITURE AUTHORITY PRESCRIBED BY THE BOARD OF DIRECTORS; (C) EMPLOY AGENTS; AND (D) CARRY INTO EXECUTION SUCH OTHER MEASURES AS IT DETERMINES WILL PROMOTE THE PURPOSE OF THE ORGANIZATION. THE COMMITTEE ALSO MAY EXERCISE, WHEN THE BOARD IS NOT IN SESSION, ALL OF THE AUTHORITY OF THE BOARD IN THE MANAGEMENT OF THE BUSINESS AND AFFAIRS OF THE ORGANIZATION WITH CERTAIN EXCEPTIONS SUCH AS REPEALING ANY BOARD RESOLUTIONS, AMENDING THE ORGANIZATION'S ARTICLES OR BYLAWS, OR MERGING OR DISSOLVING THE ORGANIZATION. THIS DELEGATION DOES NOT RELIEVE THE BOARD OF ANY OF ITS RESPONSIBILITIES IMPOSED BY LAW, AND THE COMMITTEE ENDEAVORS TO LIMIT ITS EXERCISE OF AUTHORITY TO TIME SENSITIVE ISSUES. Form 990, Part VI, Line 11b Review of form 990 by governing body MANAGEMENT PREPARES THE MATERIALS FOR THE FORM 990, WITH THE ASSISTANCE OF AND REVIEW BY EXTERNAL ACCOUNTANTS. SENIOR LEVEL MANAGEMENT REVIEW AND COMMENT ON THE FINAL DRAFT OF THE FORM 990 FOR SUBSEQUENT PRESENTATION TO THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS. THE AUDIT COMMITTEE REVIEWS, MAKES RECOMMENDATIONS, AND APPROVES THE FORM 990 FOR PRESENTATION TO THE BOARD OF DIRECTORS. THEREAFTER, THE BOARD OF DIRECTORS REVIEWS AND APPROVES THE FORM 990 PRIOR TO FILING. Form 990, Part VI, Line 12c Conflict of interest policy KOMEN'S CONFLICT OF INTEREST POLICY REQUIRES EVERY BOARD MEMBER, OFFICER, COMMITTEE MEMBER, ADVISORY BOARD MEMBER, AND EMPLOYEE TO AVOID CONFLICTS OF INTEREST. IT ALSO REQUIRES THESE PERSONS TO REPORT ANY ACTUAL AND/OR POTENTIAL CONFLICTS OF INTEREST AS SOON AS POSSIBLE. REPORTS ARE REVIEWED BY THE GENERAL COUNSEL'S OFFICE AND/OR AUDIT COMMITTEE, AND APPROPRIATE ACTION IS TAKEN PURSUANT TO THE CONFLICT OF INTEREST POLICY. FURTHER, KOMEN PRODUCES AN ANNUAL SURVEY REQUIRING ALL BOARD MEMBERS, OFFICERS, COMMITTEE MEMBERS, ADVISORY BOARD MEMBERS, AND EMPLOYEES TO REVIEW THE CONFLICT OF INTEREST POLICY AND DISCLOSE ANY ADDITIONAL ACTUAL/POTENTIAL CONFLICTS OF INTEREST. THESE ANNUAL DISCLOSURES ARE REVIEWED IN THE SAME MANNER. THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS RECEIVES, AND REVIEWS ALL REPORTED ACTUAL AND POTENTIAL CONFLICTS OF INTEREST AND THE RELATED ACTION TO ADDRESS THEM. Form 990, Part VI, Line 15a Process to establish compensation of top management official THE HUMAN CAPITAL MANAGEMENT COMMITTEE OF THE BOARD OF DIRECTORS ASSISTS THE BOARD IN OVERSEEING COMPENSATION POLICIES AND BEST PRACTICES. RESPONSIBILITIES INCLUDE OVERSIGHT OF THE COMPENSATION OF THE CHIEF EXECUTIVE OFFICER; THE RANGE OF COMPENSATION LEVELS FOR THE ORGANIZATION'S OTHER OFFICERS, DISQUALIFIED PERSONS, AND OTHER KEY EMPLOYEES; GRANTING THE CHIEF EXECUTIVE OFFICER WITH THE AUTHORITY TO DETERMINE COMPENSATION LEVELS WITHIN AN APPROVED RANGE; AND ANY INCENTIVE/BONUS COMPENSATION PROGRAMS, IF APPROVED. THE CURRENT POLICY WAS ADOPTED IN 2010 AND IS REVIEWED ANNUALLY. A FORMAL COMPENSATION POLICY GOVERNS PAY PRACTICES. PERIODICALLY, ALL POSITIONS IN THE ORGANIZATION ARE REVIEWED AGAINST EXTERNAL MARKET DATA BY ENGAGING INDEPENDENT EXPERTS OR ACQUIRING UPDATED MARKET DATA TO CONDUCT THE BENCHMARKING PROCESS. COMPENSATION IS THEN BASED UPON COMPARABLE MARKET RATES OF PAY WITH CONSIDERATION FOR INTERNAL EQUITY AND THE FINANCIAL POSITION OF THE ORGANIZATION. BENCHMARKING WAS CONDUCTED FOR THE CHIEF EXECUTIVE OFFICER AND ALL EXECUTIVE TEAM MEMBERS' COMPENSATION TO EXTERNAL MARKET DATA IN 2022, TO ENSURE MARKET ALIGNMENT. KOMEN PROVIDES SALARY INCREASES, PROMOTIONS AND OTHER FORMS OF COMPENSATION WITHOUT REGARD TO RACE, COLOR, RELIGION, GENDER, NATIONAL ORIGIN, DISABILITY, VETERAN STATUS OR SEXUAL ORIENTATION. Form 990, Part VI, Line 15b Process to establish compensation of other employees THE HUMAN CAPITAL MANAGEMENT COMMITTEE OF THE BOARD OF DIRECTORS ASSISTS THE BOARD IN OVERSEEING COMPENSATION POLICIES AND BEST PRACTICES. RESPONSIBILITIES INCLUDE OVERSIGHT OF THE COMPENSATION OF THE CHIEF EXECUTIVE OFFICER; THE RANGE OF COMPENSATION LEVELS FOR THE ORGANIZATION'S OTHER OFFICERS, DISQUALIFIED PERSONS, AND OTHER KEY EMPLOYEES; GRANTING THE CHIEF EXECUTIVE OFFICER WITH THE AUTHORITY TO DETERMINE COMPENSATION LEVELS WITHIN AN APPROVED RANGE; AND ANY INCENTIVE/BONUS COMPENSATION PROGRAMS, IF APPROVED. THE CURRENT POLICY WAS ADOPTED IN 2010 AND IS REVIEWED ANNUALLY. A FORMAL COMPENSATION POLICY GOVERNS PAY PRACTICES. PERIODICALLY, ALL POSITIONS IN THE ORGANIZATION ARE REVIEWED AGAINST EXTERNAL MARKET DATA BY ENGAGING INDEPENDENT EXPERTS OR ACQUIRING UPDATED MARKET DATA TO CONDUCT THE BENCHMARKING PROCESS. COMPENSATION IS THEN BASED UPON COMPARABLE MARKET RATES OF PAY WITH CONSIDERATION FOR INTERNAL EQUITY AND THE FINANCIAL POSITION OF THE ORGANIZATION. BENCHMARKING WAS CONDUCTED FOR THE CHIEF EXECUTIVE OFFICER AND ALL EXECUTIVE TEAM MEMBERS' COMPENSATION TO EXTERNAL MARKET DATA IN 2022, TO ENSURE MARKET ALIGNMENT. KOMEN PROVIDES SALARY INCREASES, PROMOTIONS AND OTHER FORMS OF COMPENSATION WITHOUT REGARD TO RACE, COLOR, RELIGION, GENDER, NATIONAL ORIGIN, DISABILITY, VETERAN STATUS OR SEXUAL ORIENTATION. Form 990, Part VI, Line 19 Required documents available to the public KOMEN'S FINANCIAL STATEMENTS AND THE FORM 990 ARE PUBLICLY AVAILABLE ON OUR WEBSITE. THE CERTIFICATE OF FORMATION IS AVAILABLE FROM THE TEXAS SECRETARY OF STATE AND OTHER GOVERNING DOCUMENTS ARE MADE AVAILABLE AS REQUIRED BY STATE LAW. FORM 1023 AND THE CONFLICT OF INTEREST POLICY ARE NOT PUBLISHED ONLINE BUT ARE AVAILABLE TO THE PUBLIC UPON REQUEST. Form 990, Part IX, Line 1 FOR NEARLY 40 YEARS, SUSAN G. KOMEN HAS WORKED TO FULFILL ITS VISION OF CREATING A WORLD WITHOUT BREAST CANCER THROUGH ITS MISSION OF SAVING LIVES BY MEETING THE MOST CRITICAL NEEDS IN OUR COMMUNITIES AND INVESTING IN BREAKTHROUGH RESEARCH TO BETTER DETECT, PREVENT, TREAT BREAST CANCERS. OVER THE LAST TWO YEARS, KOMEN CONTINUED TO IMPLEMENT A SERIES OF CHANGES BEGUN IN 2020 TO STRENGTHEN ITS FINANCIAL AND OPERATIONAL POSITION IN RESPONSE TO THE CHANGING NEEDS OF THE BREAST CANCER COMMUNITY AND ECONOMIC CONDITIONS RESULTING FROM THE COVID-19 PANDEMIC. KOMEN HAS NEARLY COMPLETED THE CONSOLIDATION OF ALL OPERATIONS OF ITS INDEPENDENT AFFILIATES INTO ITS HEADQUARTERS ORGANIZATION, RESULTING IN A SINGLE ORGANIZATION. THIS CONSOLIDATION IS ENABLING KOMEN TO LEVERAGE THE COMBINED EXPERTISE OF ITS MISSION LEADERS TO DELIVER A UNITED MISSION PROGRAM, UTILIZING TECHNOLOGY AS A KEY DRIVER TO CONNECT TO PEOPLE WHO NEED TO ACCESS CARE WHERE THEY ARE AND TO HELP IMPROVE THE PATIENT EXPERIENCE, AS WELL AS RESULTED IN ADMINISTRATIVE AND OPERATIONAL EFFICIENCIES. CENTRAL TO KOMEN'S VISION IS A STEADFAST COMMITMENT TO INVESTING IN BREAKTHROUGH RESEARCH. KOMEN REMAINED COMMITTED TO INVESTING IN RESEARCH FOCUSED ON ITS PRIMARY FOCUS ON METASTATIC BREAST CANCER AND UNDERSTANDING AND ELIMINATING DISPARITIES IN BREAST CANCER OUTCOMES BETWEEN BLACK AND WHITE PATIENTS. DESPITE THE ECONOMIC UNCERTAINTY AND CHALLENGING FUNDRAISING ENVIRONMENT, KOMEN AWARDED $21 MILLION IN NEW RESEARCH AWARDS. WHILE WE CONTINUE TO INVEST IN RESEARCH INTO NEW TREATMENTS, KOMEN SUPPORTS PEOPLE WHO ARE FACING BREAST CANCER TODAY THROUGH A GROWING SUITE OF PATIENT CARE SERVICES, INCLUDING DIRECT FINANCIAL ASSISTANCE THROUGH ITS TREATMENT ASSISTANCE PROGRAM, ELIGIBLE TO HELP PAY FOR EXPENSES THAT MAY SERVE AS A BARRIER TO ATTAINING THE CARE NEEDED TO SURVIVE, SUCH AS CO-PAYS, TRANSPORTATION, CHILDCARE OR RENT. Form 990, Part XI, Line 9 Other changes in net assets or fund balances RESCINDED GRANTS - 589946; Event Cost Reclass - 27703;